معرفی
Jill Gaidos is an Associate Professor of Medicine at Yale School of Medicine, affiliated with the Department of Internal Medicine, Section of Digestive Diseases. She serves as Director of Clinical Research for the Yale Inflammatory Bowel Disease (IBD) Program and Vice Chief of Gastroenterology. Previously, she was a faculty member at Virginia Commonwealth University (VCU), where she directed the IBD program and GI clinics.
Her educational background includes an MD from Virginia Commonwealth University, followed by internal medicine training and a gastroenterology fellowship at VCU and the University of Florida, where she also completed the Advanced Postgraduate Program in Clinical Investigation.
Dr. Gaidos's research focuses on inflammatory bowel disease, with particular emphasis on Crohn’s disease, ulcerative colitis, and microscopic colitis. Her work explores treatment optimization, patient outcomes, health disparities, fatigue, and healthcare access. She leads numerous clinical trials and has contributed significantly to national discourse through leadership roles in the Crohn's and Colitis Foundation and the American College of Gastroenterology.
Her recent publications reflect a strong trend in clinical and translational research, addressing real-world challenges in IBD management such as treatment delays, language barriers, fatigue impact, and post-procedural flares. These studies are published in top-tier gastroenterology journals and often involve multidisciplinary collaboration.
- Cassell Connolly Elite Top Doctors 2024
- Cassel Connolly Top Doctor 2023
- Crohn’s and Colitis Foundation Women in IBD Leadership Program 2022
- American College of Gastroenterology Advanced Leadership Development Program 2022
- Cassell Connolly Top Doctor for 2022
Dr. Gaidos is actively involved in clinical research mentoring and education. She leads the OPTIMIZE clinical trial and collaborates with frequent co-authors such as Deborah Proctor, Badr Al Bawardy, and David Assis. Her work is centered on improving patient-centered outcomes and advancing the understanding of IBD through rigorous clinical investigation.
She is a key member of the Yale Inflammatory Bowel Disease Program, contributing to both clinical care and research innovation. Her leadership in national educational initiatives and clinical trial design underscores her role as a leading figure in the IBD community.
